Symptomtext
only received the liquid portion with no reported adverse event; Initial information received on 09-Nov-2022 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 5 months old female patient who only received the liquid portion with no reported adverse event. (DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(VERO)/HIB(PRP/T) VACCINE [PENTACEL (VERO)]. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included PNEUMOCOCCAL VACCINE CONJ 7V (CRM197) (PREVNAR). On 01-Nov-2022, the patient received a dose of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(VERO)/HIB(PRP/T) VACCINE (lot UJ684AA and Expiration Date :16-Sep-2023)Strength: standard at a dose of 0.5 ml Total via intramuscular route in the left vastus lateralis for Immunization. On an unknown date the patient only received the liquid portion with no reported adverse event (incorrect product formulation administered)(unknown latency). Reportedly, stated 2 patients received PENTACEL. One patient received the full dose, the other only received the liquid portion. HCP isn't sure which patient received the full dose. Caller states that she has two patients that received Pentacel and realized that they had an extra Hib dose and only one was given. Caller states that she realized as she was providing the lot and expiation information that the second patients Pentacel were from the state vaccine and he received his full dose. Caller states that another patient did not receive a full dose of Pentacel because last month she 5 doses and now she has 3 and half. Action taken was not applicable. At time of reporting, the outcome was Unknown for the event. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.